AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Helicase with zinc finger domain 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BYK8

UPID:

HELZ2_HUMAN

Alternative names:

ATP-dependent helicase PRIC285; Helicase with zinc finger 2, transcriptional coactivator; PPAR-alpha-interacting complex protein 285; PPAR-gamma DNA-binding domain-interacting protein 1; Peroxisomal proliferator-activated receptor A-interacting complex 285 kDa protein

Alternative UPACC:

Q9BYK8; Q3C2G2; Q4VXQ1; Q8TEF3; Q96ND3; Q9C094

Background:

Helicase with zinc finger domain 2, known by alternative names such as ATP-dependent helicase PRIC285 and PPAR-gamma DNA-binding domain-interacting protein 1, plays a pivotal role as a transcriptional coactivator. It interacts with nuclear receptors including PPARA, PPARG, THRA, THRB, and RXRA, facilitating the transcription process.

Therapeutic significance:

Understanding the role of Helicase with zinc finger domain 2 could open doors to potential therapeutic strategies. Its interaction with key nuclear receptors highlights its importance in gene expression regulation, suggesting its potential in targeted therapy development.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.